"Company's formulation facility at Dahej was inspected by United States Food and Drug Administration (USFDA) from April 3 to 7, 2017," Ajanta Pharma said in a filing to BSE.
At the end of the inspection, no Form 483 was issued to the company, it added.
Form 483 is issued to a company's management after completion of inspection of its facility to notify regarding objectionable conditions.
Shares of Ajanta Pharma were trading 1.24 per cent up at at Rs 1,741 apiece on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content